ThruFlo Endovascular Secures Seed Funding to Advance First Purpose-Built Flow Diverter for Bifurcation AneurysmsIRVINE, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- ThruFlo Endovascular, Inc., a neuro-endovascular medical device company, today announced the completion of seed funding led by Atlas MedInnovation (Irvine, CA) to accelerate development of its novel bifurcated flow diverter platform. Proceeds will be used to establish formal R&D operations, complete device design, initiate additional pre-clinical studies, and submit an Investigational Device Exemption (IDE) application to the FDA.
